Trials / Completed
CompletedNCT02023996
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need serial scans or serial blood draws. This study is based on a cohort expansion. All data is appropriately reported as there is only one study cohort
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 89Zr-DFO-trastuzumab | |
| DEVICE | PET imaging |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2023-06-27
- Completion
- 2023-06-27
- First posted
- 2013-12-30
- Last updated
- 2024-12-10
- Results posted
- 2024-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02023996. Inclusion in this directory is not an endorsement.